1007488-29-0

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
(1-ethyl-1H-pyrazol-5-yl)Methanol is utilized as a chemical intermediate for the synthesis of various pharmaceuticals, leveraging its unique structure to contribute to the development of new therapeutic agents.
Used in Organic Synthesis:
In the field of organic chemistry, (1-ethyl-1H-pyrazol-5-yl)Methanol serves as a key building block, enabling the creation of a range of organic compounds with diverse applications.
Used in Chemical Production:
(1-ethyl-1H-pyrazol-5-yl)Methanol is employed as a precursor in the production of other chemicals, highlighting its versatility and importance in the chemical industry.
Used in Medicinal Chemistry:
(1-ethyl-1H-pyrazol-5-yl)Methanol is investigated for its anti-inflammatory and analgesic activities, making it a subject of interest for researchers seeking novel treatments for pain and inflammation-related conditions.
Used in Anti-Inflammatory Applications:
In the medical field, (1-ethyl-1H-pyrazol-5-yl)Methanol is considered for its potential as an anti-inflammatory agent, which could be beneficial in managing conditions characterized by inflammation.
Used in Analgesic Applications:
(1-ethyl-1H-pyrazol-5-yl)Methanol is also explored for its analgesic properties, indicating its potential use in pain management therapies.

Upstream product

• 902837-62-1 1-ethyl-1H-pyrazole-5-carbaldehyde 
• 400755-43-3 1-ethyl-1H-pyrazole-5-carboxylic acid 
• 2817-71-2 1-ethyl-1H-pyrazole 
• 75-03-6 ethyl iodide 

Downstream Products

• 1260659-26-4 2-(1-ethyl-1H-pyrazol-5-yl)acetonitrile 
• 1607023-15-3 5-(4-chloro-3-methoxyphenyl)-3-(1-ethyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1607023-16-4 5-(4-chlorophenyl)-3-(1-ethyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 
• 1607023-48-2 5-(3,4-dichlorophenyl)-3-(1-ethyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyrimidin-7(4H)-one 

Relevant academic research and scientific papers

Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor

Myeloid cell leukemia 1 (Mcl-1) has emerged as an attractive target for cancer therapy. It is an antiapoptotic member of the Bcl-2 family of proteins, whose upregulation in human cancers is associated with high tumor grade, poor survival, and resistance to chemotherapy. Here we report the discovery of our clinical candidate S64315, a selective small molecule inhibitor of Mcl-1. Starting from a fragment derived lead compound, we have conducted structure guided optimization that has led to a significant (3 log) improvement of target affinity as well as cellular potency. The presence of hindered rotation along a biaryl axis has conferred high selectivity to the compounds against other members of the Bcl-2 family. During optimization, we have also established predictive PD markers of Mcl-1 inhibition and achieved both efficient in vitro cell killing and tumor regression in Mcl-1 dependent cancer models. The preclinical candidate has drug-like properties that have enabled its development and entry into clinical trials.

ADENOSINE RECEPTOR BINDING COMPOUNDS

The present invention relates to pharmaceutical compounds and compositions of Formula (I) and methods of treatment using the compounds and compositions, especially for the treatment and/or prevention of a proliferation disorder, such as cancer. Compounds of Formula (I) as further described herein are shown modulators of the adenosine A2A receptor and exhibit antiproliferative activity. Accordingly, these compounds are useful to treat proliferative disorders such as cancer, and other adenosine receptor-related conditions including an inflammatory disease, renal disease, diabetes, vascular disease, lung disease, or an autoimmune disease.

NEW THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, R12, X, A and n are as defined in the description.

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS

The present invention relates to pyrimidine derivatives of Formula (Ia) and (Ib) (including tautomers, isomers, prodrugs, and pharmaceutically acceptable salts thereof). Said compounds are useful in the treatment of pain (such as neuropathic pain), inflammation, and epilepsy (by acting as anticonvulsants). Methods of medical treatment making use of said compounds, as well as additional compounds of Formula (IIa) and (IIb), are also disclosed.